nodes	percent_of_prediction	percent_of_DWPC	metapath
Tizanidine—NISCH—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0103	0.276	CbGpPWpGaD
Tizanidine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00367	0.098	CbGpPWpGaD
Tizanidine—Drowsiness—Methotrexate—bone cancer	0.00145	0.0015	CcSEcCtD
Tizanidine—Depression—Methotrexate—bone cancer	0.00144	0.0015	CcSEcCtD
Tizanidine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00143	0.00149	CcSEcCtD
Tizanidine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00143	0.00149	CcSEcCtD
Tizanidine—Muscular weakness—Doxorubicin—bone cancer	0.00143	0.00149	CcSEcCtD
Tizanidine—Renal failure—Methotrexate—bone cancer	0.00142	0.00148	CcSEcCtD
Tizanidine—Conjunctivitis—Methotrexate—bone cancer	0.00141	0.00146	CcSEcCtD
Tizanidine—Asthma—Doxorubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Tizanidine—Influenza—Doxorubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Tizanidine—Dysphagia—Doxorubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Tizanidine—Pollakiuria—Epirubicin—bone cancer	0.0014	0.00146	CcSEcCtD
Tizanidine—Sweating—Methotrexate—bone cancer	0.00139	0.00144	CcSEcCtD
Tizanidine—Feeling abnormal—Cisplatin—bone cancer	0.00139	0.00144	CcSEcCtD
Tizanidine—Haematuria—Methotrexate—bone cancer	0.00138	0.00143	CcSEcCtD
Tizanidine—Weight decreased—Epirubicin—bone cancer	0.00137	0.00143	CcSEcCtD
Tizanidine—Hyperglycaemia—Epirubicin—bone cancer	0.00137	0.00142	CcSEcCtD
Tizanidine—Angina pectoris—Doxorubicin—bone cancer	0.00137	0.00142	CcSEcCtD
Tizanidine—Hepatobiliary disease—Methotrexate—bone cancer	0.00137	0.00142	CcSEcCtD
Tizanidine—Pneumonia—Epirubicin—bone cancer	0.00136	0.00141	CcSEcCtD
Tizanidine—Drowsiness—Epirubicin—bone cancer	0.00135	0.00141	CcSEcCtD
Tizanidine—Bronchitis—Doxorubicin—bone cancer	0.00135	0.0014	CcSEcCtD
Tizanidine—Agranulocytosis—Methotrexate—bone cancer	0.00135	0.0014	CcSEcCtD
Tizanidine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00135	0.036	CbGpPWpGaD
Tizanidine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00134	0.00139	CcSEcCtD
Tizanidine—Renal failure—Epirubicin—bone cancer	0.00133	0.00138	CcSEcCtD
Tizanidine—Body temperature increased—Cisplatin—bone cancer	0.00133	0.00138	CcSEcCtD
Tizanidine—Neuropathy peripheral—Epirubicin—bone cancer	0.00133	0.00138	CcSEcCtD
Tizanidine—Jaundice—Epirubicin—bone cancer	0.00132	0.00137	CcSEcCtD
Tizanidine—Conjunctivitis—Epirubicin—bone cancer	0.00132	0.00137	CcSEcCtD
Tizanidine—Haemoglobin—Methotrexate—bone cancer	0.0013	0.00136	CcSEcCtD
Tizanidine—Haemorrhage—Methotrexate—bone cancer	0.0013	0.00135	CcSEcCtD
Tizanidine—Hepatitis—Methotrexate—bone cancer	0.0013	0.00135	CcSEcCtD
Tizanidine—Sweating—Epirubicin—bone cancer	0.0013	0.00135	CcSEcCtD
Tizanidine—Pollakiuria—Doxorubicin—bone cancer	0.0013	0.00135	CcSEcCtD
Tizanidine—Haematuria—Epirubicin—bone cancer	0.00129	0.00134	CcSEcCtD
Tizanidine—Pharyngitis—Methotrexate—bone cancer	0.00129	0.00134	CcSEcCtD
Tizanidine—Urinary tract disorder—Methotrexate—bone cancer	0.00128	0.00133	CcSEcCtD
Tizanidine—Hepatobiliary disease—Epirubicin—bone cancer	0.00128	0.00133	CcSEcCtD
Tizanidine—Urethral disorder—Methotrexate—bone cancer	0.00127	0.00132	CcSEcCtD
Tizanidine—Weight decreased—Doxorubicin—bone cancer	0.00127	0.00132	CcSEcCtD
Tizanidine—Sinusitis—Epirubicin—bone cancer	0.00127	0.00132	CcSEcCtD
Tizanidine—Hyperglycaemia—Doxorubicin—bone cancer	0.00127	0.00132	CcSEcCtD
Tizanidine—Agranulocytosis—Epirubicin—bone cancer	0.00126	0.00131	CcSEcCtD
Tizanidine—Pneumonia—Doxorubicin—bone cancer	0.00126	0.00131	CcSEcCtD
Tizanidine—Drowsiness—Doxorubicin—bone cancer	0.00125	0.0013	CcSEcCtD
Tizanidine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00124	0.00129	CcSEcCtD
Tizanidine—Hypersensitivity—Cisplatin—bone cancer	0.00124	0.00129	CcSEcCtD
Tizanidine—Bradycardia—Epirubicin—bone cancer	0.00124	0.00129	CcSEcCtD
Tizanidine—Renal failure—Doxorubicin—bone cancer	0.00123	0.00128	CcSEcCtD
Tizanidine—Erythema multiforme—Methotrexate—bone cancer	0.00123	0.00128	CcSEcCtD
Tizanidine—Neuropathy peripheral—Doxorubicin—bone cancer	0.00123	0.00128	CcSEcCtD
Tizanidine—Haemoglobin—Epirubicin—bone cancer	0.00122	0.00127	CcSEcCtD
Tizanidine—Jaundice—Doxorubicin—bone cancer	0.00122	0.00127	CcSEcCtD
Tizanidine—Rhinitis—Epirubicin—bone cancer	0.00122	0.00127	CcSEcCtD
Tizanidine—Conjunctivitis—Doxorubicin—bone cancer	0.00122	0.00127	CcSEcCtD
Tizanidine—Hepatitis—Epirubicin—bone cancer	0.00121	0.00126	CcSEcCtD
Tizanidine—Haemorrhage—Epirubicin—bone cancer	0.00121	0.00126	CcSEcCtD
Tizanidine—Tinnitus—Methotrexate—bone cancer	0.00121	0.00126	CcSEcCtD
Tizanidine—Asthenia—Cisplatin—bone cancer	0.00121	0.00125	CcSEcCtD
Tizanidine—Pharyngitis—Epirubicin—bone cancer	0.00121	0.00125	CcSEcCtD
Tizanidine—Cardiac disorder—Methotrexate—bone cancer	0.0012	0.00125	CcSEcCtD
Tizanidine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0012	0.0322	CbGpPWpGaD
Tizanidine—Sweating—Doxorubicin—bone cancer	0.0012	0.00125	CcSEcCtD
Tizanidine—Urinary tract disorder—Epirubicin—bone cancer	0.0012	0.00125	CcSEcCtD
Tizanidine—Haematuria—Doxorubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Tizanidine—Connective tissue disorder—Epirubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Tizanidine—Urethral disorder—Epirubicin—bone cancer	0.00119	0.00124	CcSEcCtD
Tizanidine—Hepatobiliary disease—Doxorubicin—bone cancer	0.00118	0.00123	CcSEcCtD
Tizanidine—Angiopathy—Methotrexate—bone cancer	0.00118	0.00122	CcSEcCtD
Tizanidine—Sinusitis—Doxorubicin—bone cancer	0.00117	0.00122	CcSEcCtD
Tizanidine—Immune system disorder—Methotrexate—bone cancer	0.00117	0.00122	CcSEcCtD
Tizanidine—Mediastinal disorder—Methotrexate—bone cancer	0.00117	0.00122	CcSEcCtD
Tizanidine—Agranulocytosis—Doxorubicin—bone cancer	0.00117	0.00121	CcSEcCtD
Tizanidine—Diarrhoea—Cisplatin—bone cancer	0.00115	0.0012	CcSEcCtD
Tizanidine—Erythema multiforme—Epirubicin—bone cancer	0.00115	0.00119	CcSEcCtD
Tizanidine—Alopecia—Methotrexate—bone cancer	0.00115	0.00119	CcSEcCtD
Tizanidine—Bradycardia—Doxorubicin—bone cancer	0.00114	0.00119	CcSEcCtD
Tizanidine—Mental disorder—Methotrexate—bone cancer	0.00114	0.00118	CcSEcCtD
Tizanidine—Tinnitus—Epirubicin—bone cancer	0.00113	0.00118	CcSEcCtD
Tizanidine—Haemoglobin—Doxorubicin—bone cancer	0.00113	0.00117	CcSEcCtD
Tizanidine—Cardiac disorder—Epirubicin—bone cancer	0.00113	0.00117	CcSEcCtD
Tizanidine—Rhinitis—Doxorubicin—bone cancer	0.00113	0.00117	CcSEcCtD
Tizanidine—Haemorrhage—Doxorubicin—bone cancer	0.00112	0.00117	CcSEcCtD
Tizanidine—Hepatitis—Doxorubicin—bone cancer	0.00112	0.00117	CcSEcCtD
Tizanidine—Pharyngitis—Doxorubicin—bone cancer	0.00112	0.00116	CcSEcCtD
Tizanidine—Urinary tract disorder—Doxorubicin—bone cancer	0.00111	0.00115	CcSEcCtD
Tizanidine—Connective tissue disorder—Doxorubicin—bone cancer	0.0011	0.00115	CcSEcCtD
Tizanidine—Angiopathy—Epirubicin—bone cancer	0.0011	0.00115	CcSEcCtD
Tizanidine—Urethral disorder—Doxorubicin—bone cancer	0.0011	0.00115	CcSEcCtD
Tizanidine—Immune system disorder—Epirubicin—bone cancer	0.0011	0.00114	CcSEcCtD
Tizanidine—Mediastinal disorder—Epirubicin—bone cancer	0.00109	0.00114	CcSEcCtD
Tizanidine—Back pain—Methotrexate—bone cancer	0.00109	0.00114	CcSEcCtD
Tizanidine—Arrhythmia—Epirubicin—bone cancer	0.00109	0.00113	CcSEcCtD
Tizanidine—Alopecia—Epirubicin—bone cancer	0.00107	0.00112	CcSEcCtD
Tizanidine—Vomiting—Cisplatin—bone cancer	0.00107	0.00111	CcSEcCtD
Tizanidine—Vision blurred—Methotrexate—bone cancer	0.00107	0.00111	CcSEcCtD
Tizanidine—Mental disorder—Epirubicin—bone cancer	0.00106	0.00111	CcSEcCtD
Tizanidine—Erythema multiforme—Doxorubicin—bone cancer	0.00106	0.0011	CcSEcCtD
Tizanidine—Rash—Cisplatin—bone cancer	0.00106	0.0011	CcSEcCtD
Tizanidine—Dermatitis—Cisplatin—bone cancer	0.00106	0.0011	CcSEcCtD
Tizanidine—Ill-defined disorder—Methotrexate—bone cancer	0.00105	0.00109	CcSEcCtD
Tizanidine—Tinnitus—Doxorubicin—bone cancer	0.00105	0.00109	CcSEcCtD
Tizanidine—Anaemia—Methotrexate—bone cancer	0.00104	0.00109	CcSEcCtD
Tizanidine—Cardiac disorder—Doxorubicin—bone cancer	0.00104	0.00108	CcSEcCtD
Tizanidine—Flatulence—Epirubicin—bone cancer	0.00104	0.00108	CcSEcCtD
Tizanidine—Tension—Epirubicin—bone cancer	0.00104	0.00108	CcSEcCtD
Tizanidine—Nervousness—Epirubicin—bone cancer	0.00103	0.00107	CcSEcCtD
Tizanidine—Back pain—Epirubicin—bone cancer	0.00102	0.00106	CcSEcCtD
Tizanidine—Angiopathy—Doxorubicin—bone cancer	0.00102	0.00106	CcSEcCtD
Tizanidine—Malaise—Methotrexate—bone cancer	0.00102	0.00106	CcSEcCtD
Tizanidine—Muscle spasms—Epirubicin—bone cancer	0.00102	0.00106	CcSEcCtD
Tizanidine—Immune system disorder—Doxorubicin—bone cancer	0.00102	0.00106	CcSEcCtD
Tizanidine—Vertigo—Methotrexate—bone cancer	0.00102	0.00106	CcSEcCtD
Tizanidine—Mediastinal disorder—Doxorubicin—bone cancer	0.00101	0.00105	CcSEcCtD
Tizanidine—Leukopenia—Methotrexate—bone cancer	0.00101	0.00105	CcSEcCtD
Tizanidine—Arrhythmia—Doxorubicin—bone cancer	0.001	0.00104	CcSEcCtD
Tizanidine—Nausea—Cisplatin—bone cancer	0.000998	0.00104	CcSEcCtD
Tizanidine—Vision blurred—Epirubicin—bone cancer	0.000997	0.00104	CcSEcCtD
Tizanidine—Alopecia—Doxorubicin—bone cancer	0.000993	0.00103	CcSEcCtD
Tizanidine—Mental disorder—Doxorubicin—bone cancer	0.000985	0.00102	CcSEcCtD
Tizanidine—Ill-defined disorder—Epirubicin—bone cancer	0.000981	0.00102	CcSEcCtD
Tizanidine—Convulsion—Methotrexate—bone cancer	0.000979	0.00102	CcSEcCtD
Tizanidine—Anaemia—Epirubicin—bone cancer	0.000977	0.00102	CcSEcCtD
Tizanidine—Agitation—Epirubicin—bone cancer	0.000972	0.00101	CcSEcCtD
Tizanidine—Flatulence—Doxorubicin—bone cancer	0.000964	0.001	CcSEcCtD
Tizanidine—Arthralgia—Methotrexate—bone cancer	0.000962	0.001	CcSEcCtD
Tizanidine—Tension—Doxorubicin—bone cancer	0.00096	0.000998	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000955	0.000993	CcSEcCtD
Tizanidine—Malaise—Epirubicin—bone cancer	0.000954	0.000991	CcSEcCtD
Tizanidine—Discomfort—Methotrexate—bone cancer	0.000951	0.000988	CcSEcCtD
Tizanidine—Nervousness—Doxorubicin—bone cancer	0.00095	0.000988	CcSEcCtD
Tizanidine—Vertigo—Epirubicin—bone cancer	0.00095	0.000988	CcSEcCtD
Tizanidine—Syncope—Epirubicin—bone cancer	0.000948	0.000986	CcSEcCtD
Tizanidine—Leukopenia—Epirubicin—bone cancer	0.000947	0.000984	CcSEcCtD
Tizanidine—Back pain—Doxorubicin—bone cancer	0.000947	0.000984	CcSEcCtD
Tizanidine—Muscle spasms—Doxorubicin—bone cancer	0.000941	0.000978	CcSEcCtD
Tizanidine—Confusional state—Methotrexate—bone cancer	0.00093	0.000967	CcSEcCtD
Tizanidine—Loss of consciousness—Epirubicin—bone cancer	0.00093	0.000966	CcSEcCtD
Tizanidine—Anaphylactic shock—Methotrexate—bone cancer	0.000922	0.000959	CcSEcCtD
Tizanidine—Vision blurred—Doxorubicin—bone cancer	0.000922	0.000959	CcSEcCtD
Tizanidine—Convulsion—Epirubicin—bone cancer	0.000916	0.000952	CcSEcCtD
Tizanidine—Infection—Methotrexate—bone cancer	0.000916	0.000952	CcSEcCtD
Tizanidine—Hypertension—Epirubicin—bone cancer	0.000913	0.000949	CcSEcCtD
Tizanidine—Ill-defined disorder—Doxorubicin—bone cancer	0.000908	0.000944	CcSEcCtD
Tizanidine—Nervous system disorder—Methotrexate—bone cancer	0.000904	0.00094	CcSEcCtD
Tizanidine—Anaemia—Doxorubicin—bone cancer	0.000904	0.00094	CcSEcCtD
Tizanidine—Thrombocytopenia—Methotrexate—bone cancer	0.000903	0.000939	CcSEcCtD
Tizanidine—Arthralgia—Epirubicin—bone cancer	0.0009	0.000936	CcSEcCtD
Tizanidine—Agitation—Doxorubicin—bone cancer	0.000899	0.000935	CcSEcCtD
Tizanidine—Anxiety—Epirubicin—bone cancer	0.000897	0.000933	CcSEcCtD
Tizanidine—Skin disorder—Methotrexate—bone cancer	0.000896	0.000931	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000894	0.000929	CcSEcCtD
Tizanidine—Hyperhidrosis—Methotrexate—bone cancer	0.000892	0.000927	CcSEcCtD
Tizanidine—Discomfort—Epirubicin—bone cancer	0.00089	0.000925	CcSEcCtD
Tizanidine—Malaise—Doxorubicin—bone cancer	0.000882	0.000917	CcSEcCtD
Tizanidine—Dry mouth—Epirubicin—bone cancer	0.000881	0.000915	CcSEcCtD
Tizanidine—Vertigo—Doxorubicin—bone cancer	0.000879	0.000914	CcSEcCtD
Tizanidine—Syncope—Doxorubicin—bone cancer	0.000878	0.000912	CcSEcCtD
Tizanidine—Leukopenia—Doxorubicin—bone cancer	0.000876	0.00091	CcSEcCtD
Tizanidine—Confusional state—Epirubicin—bone cancer	0.00087	0.000905	CcSEcCtD
Tizanidine—Oedema—Epirubicin—bone cancer	0.000863	0.000897	CcSEcCtD
Tizanidine—Anaphylactic shock—Epirubicin—bone cancer	0.000863	0.000897	CcSEcCtD
Tizanidine—Hypotension—Methotrexate—bone cancer	0.000862	0.000896	CcSEcCtD
Tizanidine—Loss of consciousness—Doxorubicin—bone cancer	0.00086	0.000894	CcSEcCtD
Tizanidine—Infection—Epirubicin—bone cancer	0.000857	0.000891	CcSEcCtD
Tizanidine—Shock—Epirubicin—bone cancer	0.000849	0.000883	CcSEcCtD
Tizanidine—Convulsion—Doxorubicin—bone cancer	0.000848	0.000881	CcSEcCtD
Tizanidine—Nervous system disorder—Epirubicin—bone cancer	0.000846	0.00088	CcSEcCtD
Tizanidine—Thrombocytopenia—Epirubicin—bone cancer	0.000845	0.000878	CcSEcCtD
Tizanidine—Hypertension—Doxorubicin—bone cancer	0.000845	0.000878	CcSEcCtD
Tizanidine—Tachycardia—Epirubicin—bone cancer	0.000842	0.000876	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00084	0.000873	CcSEcCtD
Tizanidine—Skin disorder—Epirubicin—bone cancer	0.000838	0.000871	CcSEcCtD
Tizanidine—Hyperhidrosis—Epirubicin—bone cancer	0.000834	0.000867	CcSEcCtD
Tizanidine—Arthralgia—Doxorubicin—bone cancer	0.000833	0.000866	CcSEcCtD
Tizanidine—Anxiety—Doxorubicin—bone cancer	0.00083	0.000863	CcSEcCtD
Tizanidine—Paraesthesia—Methotrexate—bone cancer	0.000828	0.000861	CcSEcCtD
Tizanidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000827	0.00086	CcSEcCtD
Tizanidine—Discomfort—Doxorubicin—bone cancer	0.000823	0.000856	CcSEcCtD
Tizanidine—Dyspnoea—Methotrexate—bone cancer	0.000822	0.000855	CcSEcCtD
Tizanidine—Somnolence—Methotrexate—bone cancer	0.00082	0.000852	CcSEcCtD
Tizanidine—Dry mouth—Doxorubicin—bone cancer	0.000815	0.000847	CcSEcCtD
Tizanidine—Dyspepsia—Methotrexate—bone cancer	0.000812	0.000844	CcSEcCtD
Tizanidine—Hypotension—Epirubicin—bone cancer	0.000807	0.000838	CcSEcCtD
Tizanidine—Confusional state—Doxorubicin—bone cancer	0.000805	0.000837	CcSEcCtD
Tizanidine—Oedema—Doxorubicin—bone cancer	0.000799	0.00083	CcSEcCtD
Tizanidine—Anaphylactic shock—Doxorubicin—bone cancer	0.000799	0.00083	CcSEcCtD
Tizanidine—Fatigue—Methotrexate—bone cancer	0.000795	0.000827	CcSEcCtD
Tizanidine—Infection—Doxorubicin—bone cancer	0.000793	0.000825	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000786	0.000817	CcSEcCtD
Tizanidine—Shock—Doxorubicin—bone cancer	0.000786	0.000817	CcSEcCtD
Tizanidine—Nervous system disorder—Doxorubicin—bone cancer	0.000783	0.000814	CcSEcCtD
Tizanidine—Thrombocytopenia—Doxorubicin—bone cancer	0.000782	0.000813	CcSEcCtD
Tizanidine—Tachycardia—Doxorubicin—bone cancer	0.000779	0.00081	CcSEcCtD
Tizanidine—Skin disorder—Doxorubicin—bone cancer	0.000776	0.000806	CcSEcCtD
Tizanidine—Paraesthesia—Epirubicin—bone cancer	0.000775	0.000806	CcSEcCtD
Tizanidine—Hyperhidrosis—Doxorubicin—bone cancer	0.000772	0.000802	CcSEcCtD
Tizanidine—Dyspnoea—Epirubicin—bone cancer	0.00077	0.0008	CcSEcCtD
Tizanidine—Somnolence—Epirubicin—bone cancer	0.000767	0.000798	CcSEcCtD
Tizanidine—Feeling abnormal—Methotrexate—bone cancer	0.00076	0.00079	CcSEcCtD
Tizanidine—Dyspepsia—Epirubicin—bone cancer	0.00076	0.00079	CcSEcCtD
Tizanidine—Gastrointestinal pain—Methotrexate—bone cancer	0.000754	0.000784	CcSEcCtD
Tizanidine—Hypotension—Doxorubicin—bone cancer	0.000746	0.000776	CcSEcCtD
Tizanidine—Fatigue—Epirubicin—bone cancer	0.000744	0.000773	CcSEcCtD
Tizanidine—Constipation—Epirubicin—bone cancer	0.000738	0.000767	CcSEcCtD
Tizanidine—Urticaria—Methotrexate—bone cancer	0.000733	0.000762	CcSEcCtD
Tizanidine—Abdominal pain—Methotrexate—bone cancer	0.000729	0.000758	CcSEcCtD
Tizanidine—Body temperature increased—Methotrexate—bone cancer	0.000729	0.000758	CcSEcCtD
Tizanidine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000728	0.000756	CcSEcCtD
Tizanidine—Paraesthesia—Doxorubicin—bone cancer	0.000717	0.000745	CcSEcCtD
Tizanidine—Dyspnoea—Doxorubicin—bone cancer	0.000712	0.00074	CcSEcCtD
Tizanidine—Feeling abnormal—Epirubicin—bone cancer	0.000711	0.000739	CcSEcCtD
Tizanidine—Somnolence—Doxorubicin—bone cancer	0.00071	0.000738	CcSEcCtD
Tizanidine—Gastrointestinal pain—Epirubicin—bone cancer	0.000706	0.000734	CcSEcCtD
Tizanidine—Dyspepsia—Doxorubicin—bone cancer	0.000703	0.000731	CcSEcCtD
Tizanidine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000695	0.0186	CbGpPWpGaD
Tizanidine—Fatigue—Doxorubicin—bone cancer	0.000689	0.000716	CcSEcCtD
Tizanidine—Urticaria—Epirubicin—bone cancer	0.000686	0.000713	CcSEcCtD
Tizanidine—Constipation—Doxorubicin—bone cancer	0.000683	0.00071	CcSEcCtD
Tizanidine—Abdominal pain—Epirubicin—bone cancer	0.000682	0.000709	CcSEcCtD
Tizanidine—Body temperature increased—Epirubicin—bone cancer	0.000682	0.000709	CcSEcCtD
Tizanidine—Hypersensitivity—Methotrexate—bone cancer	0.00068	0.000706	CcSEcCtD
Tizanidine—Asthenia—Methotrexate—bone cancer	0.000662	0.000688	CcSEcCtD
Tizanidine—Feeling abnormal—Doxorubicin—bone cancer	0.000658	0.000684	CcSEcCtD
Tizanidine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000653	0.000679	CcSEcCtD
Tizanidine—Pruritus—Methotrexate—bone cancer	0.000653	0.000678	CcSEcCtD
Tizanidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000651	0.0174	CbGpPWpGaD
Tizanidine—Hypersensitivity—Epirubicin—bone cancer	0.000636	0.000661	CcSEcCtD
Tizanidine—Urticaria—Doxorubicin—bone cancer	0.000634	0.000659	CcSEcCtD
Tizanidine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000632	0.0169	CbGpPWpGaD
Tizanidine—Body temperature increased—Doxorubicin—bone cancer	0.000631	0.000656	CcSEcCtD
Tizanidine—Abdominal pain—Doxorubicin—bone cancer	0.000631	0.000656	CcSEcCtD
Tizanidine—Diarrhoea—Methotrexate—bone cancer	0.000631	0.000656	CcSEcCtD
Tizanidine—Asthenia—Epirubicin—bone cancer	0.000619	0.000644	CcSEcCtD
Tizanidine—Pruritus—Epirubicin—bone cancer	0.000611	0.000635	CcSEcCtD
Tizanidine—Dizziness—Methotrexate—bone cancer	0.00061	0.000634	CcSEcCtD
Tizanidine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000605	0.0162	CbGpPWpGaD
Tizanidine—Diarrhoea—Epirubicin—bone cancer	0.000591	0.000614	CcSEcCtD
Tizanidine—Hypersensitivity—Doxorubicin—bone cancer	0.000588	0.000612	CcSEcCtD
Tizanidine—Vomiting—Methotrexate—bone cancer	0.000586	0.00061	CcSEcCtD
Tizanidine—Rash—Methotrexate—bone cancer	0.000582	0.000604	CcSEcCtD
Tizanidine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000581	0.0155	CbGpPWpGaD
Tizanidine—Dermatitis—Methotrexate—bone cancer	0.000581	0.000604	CcSEcCtD
Tizanidine—Asthenia—Doxorubicin—bone cancer	0.000573	0.000596	CcSEcCtD
Tizanidine—Dizziness—Epirubicin—bone cancer	0.000571	0.000593	CcSEcCtD
Tizanidine—Pruritus—Doxorubicin—bone cancer	0.000565	0.000587	CcSEcCtD
Tizanidine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000559	0.0149	CbGpPWpGaD
Tizanidine—Vomiting—Epirubicin—bone cancer	0.000549	0.00057	CcSEcCtD
Tizanidine—Nausea—Methotrexate—bone cancer	0.000548	0.000569	CcSEcCtD
Tizanidine—Diarrhoea—Doxorubicin—bone cancer	0.000546	0.000568	CcSEcCtD
Tizanidine—Rash—Epirubicin—bone cancer	0.000544	0.000566	CcSEcCtD
Tizanidine—Dermatitis—Epirubicin—bone cancer	0.000544	0.000565	CcSEcCtD
Tizanidine—Dizziness—Doxorubicin—bone cancer	0.000528	0.000549	CcSEcCtD
Tizanidine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000518	0.0139	CbGpPWpGaD
Tizanidine—Nausea—Epirubicin—bone cancer	0.000513	0.000533	CcSEcCtD
Tizanidine—Vomiting—Doxorubicin—bone cancer	0.000508	0.000528	CcSEcCtD
Tizanidine—Clonidine—CYP3A4—bone cancer	0.000506	1	CrCbGaD
Tizanidine—Rash—Doxorubicin—bone cancer	0.000504	0.000523	CcSEcCtD
Tizanidine—Dermatitis—Doxorubicin—bone cancer	0.000503	0.000523	CcSEcCtD
Tizanidine—ADRA2C—Regulation of insulin secretion—GNA11—bone cancer	0.000486	0.013	CbGpPWpGaD
Tizanidine—Nausea—Doxorubicin—bone cancer	0.000474	0.000493	CcSEcCtD
Tizanidine—ADRA2A—Regulation of insulin secretion—GNA11—bone cancer	0.000395	0.0106	CbGpPWpGaD
Tizanidine—ADRA2C—Integration of energy metabolism—GNA11—bone cancer	0.000382	0.0102	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—GRM4—bone cancer	0.000382	0.0102	CbGpPWpGaD
Tizanidine—ADRA2B—G alpha (i) signalling events—RGS1—bone cancer	0.000382	0.0102	CbGpPWpGaD
Tizanidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00038	0.0102	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—GRM4—bone cancer	0.000356	0.00953	CbGpPWpGaD
Tizanidine—ADRA2C—G alpha (i) signalling events—RGS1—bone cancer	0.000356	0.00953	CbGpPWpGaD
Tizanidine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000328	0.00876	CbGpPWpGaD
Tizanidine—ADRA2A—Integration of energy metabolism—GNA11—bone cancer	0.00031	0.0083	CbGpPWpGaD
Tizanidine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000298	0.00798	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—GRM4—bone cancer	0.000289	0.00774	CbGpPWpGaD
Tizanidine—ADRA2A—G alpha (i) signalling events—RGS1—bone cancer	0.000289	0.00774	CbGpPWpGaD
Tizanidine—ADRA2B—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000245	0.00654	CbGpPWpGaD
Tizanidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000241	0.00645	CbGpPWpGaD
Tizanidine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000238	0.00636	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—GRM4—bone cancer	0.000231	0.00618	CbGpPWpGaD
Tizanidine—ADRA2C—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000229	0.00611	CbGpPWpGaD
Tizanidine—ADRA2B—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000224	0.00599	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—GRM4—bone cancer	0.000216	0.00577	CbGpPWpGaD
Tizanidine—ADRA2C—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000209	0.00559	CbGpPWpGaD
Tizanidine—ADRA2B—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000203	0.00543	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—GRM1—bone cancer	0.0002	0.00535	CbGpPWpGaD
Tizanidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000196	0.00523	CbGpPWpGaD
Tizanidine—ADRA2C—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00019	0.00507	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—GRM1—bone cancer	0.000187	0.005	CbGpPWpGaD
Tizanidine—ADRA2A—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000186	0.00497	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—GRM4—bone cancer	0.000175	0.00469	CbGpPWpGaD
Tizanidine—ADRA2A—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00017	0.00454	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000161	0.0043	CbGpPWpGaD
Tizanidine—ADRA2A—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000154	0.00412	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—GRM1—bone cancer	0.000152	0.00406	CbGpPWpGaD
Tizanidine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000152	0.00406	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR ligand binding—SMO—bone cancer	0.000141	0.00377	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—NDUFA12—bone cancer	0.000139	0.00371	CbGpPWpGaD
Tizanidine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000137	0.00367	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000132	0.00353	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR ligand binding—SMO—bone cancer	0.000132	0.00352	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—GRM4—bone cancer	0.000131	0.00349	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—RGS1—bone cancer	0.000131	0.00349	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—SPARC—bone cancer	0.000126	0.00337	CbGpPWpGaD
Tizanidine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000124	0.00331	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—GRM4—bone cancer	0.000122	0.00326	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—RGS1—bone cancer	0.000122	0.00326	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000119	0.00319	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—RGS1—bone cancer	0.000119	0.00317	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—GRM4—bone cancer	0.000119	0.00317	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—SPARC—bone cancer	0.000118	0.00315	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—GNA11—bone cancer	0.000115	0.00309	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—NT5C3A—bone cancer	0.000115	0.00308	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—GRM1—bone cancer	0.000113	0.00303	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—NDUFA12—bone cancer	0.000113	0.00302	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—RGS1—bone cancer	0.000111	0.00296	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—GRM4—bone cancer	0.000111	0.00296	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—GNA11—bone cancer	0.000108	0.00288	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR ligand binding—SMO—bone cancer	0.000107	0.00286	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—GRM1—bone cancer	0.000106	0.00283	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—IL3—bone cancer	0.000105	0.0028	CbGpPWpGaD
Tizanidine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000104	0.00278	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—GRM1—bone cancer	0.000103	0.00275	CbGpPWpGaD
Tizanidine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000102	0.00274	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—GRM4—bone cancer	9.9e-05	0.00265	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—RGS1—bone cancer	9.9e-05	0.00265	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—IL3—bone cancer	9.77e-05	0.00261	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—GRM1—bone cancer	9.6e-05	0.00257	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—SPARC—bone cancer	9.57e-05	0.00256	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.37e-05	0.00251	CbGpPWpGaD
Tizanidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.37e-05	0.00251	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—NT5C3A—bone cancer	9.35e-05	0.0025	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—GRM4—bone cancer	8.99e-05	0.0024	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—RGS1—bone cancer	8.99e-05	0.0024	CbGpPWpGaD
Tizanidine—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.89e-05	0.00238	CbGpPWpGaD
Tizanidine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	8.76e-05	0.00234	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—GNA11—bone cancer	8.76e-05	0.00234	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—GRM1—bone cancer	8.59e-05	0.0023	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—IL3—bone cancer	7.94e-05	0.00212	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—GRM1—bone cancer	7.8e-05	0.00208	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—GNA11—bone cancer	7.29e-05	0.00195	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—SMO—bone cancer	7.24e-05	0.00194	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—GRM4—bone cancer	7e-05	0.00187	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—RGS1—bone cancer	7e-05	0.00187	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—PLAU—bone cancer	6.86e-05	0.00183	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—GNA11—bone cancer	6.81e-05	0.00182	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—SMO—bone cancer	6.76e-05	0.00181	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—GNA11—bone cancer	6.62e-05	0.00177	CbGpPWpGaD
Tizanidine—ADRA2B—GPCR downstream signaling—IL3—bone cancer	6.61e-05	0.00177	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—GRM4—bone cancer	6.54e-05	0.00175	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—RGS1—bone cancer	6.54e-05	0.00175	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—PLAU—bone cancer	6.41e-05	0.00171	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—NDUFA12—bone cancer	6.23e-05	0.00166	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—GNA11—bone cancer	6.19e-05	0.00165	CbGpPWpGaD
Tizanidine—ADRA2C—GPCR downstream signaling—IL3—bone cancer	6.18e-05	0.00165	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—GRM1—bone cancer	6.07e-05	0.00162	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—IL3—bone cancer	6.01e-05	0.00161	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—GRM1—bone cancer	5.67e-05	0.00152	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—IL3—bone cancer	5.61e-05	0.0015	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—GNA11—bone cancer	5.53e-05	0.00148	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—SMO—bone cancer	5.49e-05	0.00147	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—GRM4—bone cancer	5.31e-05	0.00142	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—RGS1—bone cancer	5.31e-05	0.00142	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—PLAU—bone cancer	5.21e-05	0.00139	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—NT5C3A—bone cancer	5.16e-05	0.00138	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—ENO2—bone cancer	5.04e-05	0.00135	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—GNA11—bone cancer	5.03e-05	0.00134	CbGpPWpGaD
Tizanidine—ADRA2A—GPCR downstream signaling—IL3—bone cancer	5.02e-05	0.00134	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—DHFR—bone cancer	4.68e-05	0.00125	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—GRM1—bone cancer	4.61e-05	0.00123	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—IL3—bone cancer	4.56e-05	0.00122	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—GNA11—bone cancer	4.37e-05	0.00117	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—SMO—bone cancer	4.28e-05	0.00114	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—ENO2—bone cancer	4.09e-05	0.00109	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—SMO—bone cancer	4e-05	0.00107	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—CYP3A4—bone cancer	3.96e-05	0.00106	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—GNA11—bone cancer	3.91e-05	0.00105	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—DHFR—bone cancer	3.8e-05	0.00102	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—GNA11—bone cancer	3.65e-05	0.000977	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—ATF1—bone cancer	3.64e-05	0.000972	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—GNA11—bone cancer	3.55e-05	0.000949	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—IL3—bone cancer	3.55e-05	0.000948	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—ATF1—bone cancer	3.4e-05	0.000908	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—GSTP1—bone cancer	3.39e-05	0.000906	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—IL3—bone cancer	3.31e-05	0.000886	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—SMO—bone cancer	3.25e-05	0.000868	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—CYP3A4—bone cancer	3.22e-05	0.00086	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—TGFBR2—bone cancer	3.03e-05	0.000811	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—GNA11—bone cancer	2.97e-05	0.000794	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—IGF1R—bone cancer	2.85e-05	0.000763	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	2.83e-05	0.000758	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—ATF1—bone cancer	2.76e-05	0.000738	CbGpPWpGaD
Tizanidine—ADRA2B—Hemostasis—TP53—bone cancer	2.76e-05	0.000738	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—GSTP1—bone cancer	2.75e-05	0.000736	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IL3—bone cancer	2.69e-05	0.000719	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—IGF1R—bone cancer	2.67e-05	0.000713	CbGpPWpGaD
Tizanidine—ADRA2C—Hemostasis—TP53—bone cancer	2.58e-05	0.000689	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	2.3e-05	0.000615	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—ENO2—bone cancer	2.26e-05	0.000604	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—IGF1R—bone cancer	2.17e-05	0.000579	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—DHFR—bone cancer	2.1e-05	0.000561	CbGpPWpGaD
Tizanidine—ADRA2A—Hemostasis—TP53—bone cancer	2.09e-05	0.00056	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—KIT—bone cancer	2.07e-05	0.000553	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—GNA11—bone cancer	1.96e-05	0.000524	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—BRAF—bone cancer	1.95e-05	0.00052	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—KIT—bone cancer	1.93e-05	0.000517	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling by GPCR—EGFR—bone cancer	1.89e-05	0.000504	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—BRAF—bone cancer	1.82e-05	0.000486	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.78e-05	0.000475	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.77e-05	0.000473	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling by GPCR—EGFR—bone cancer	1.76e-05	0.000471	CbGpPWpGaD
Tizanidine—ADRA2C—Metabolism—PTGS2—bone cancer	1.76e-05	0.000469	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—MDM2—bone cancer	1.63e-05	0.000436	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—KIT—bone cancer	1.57e-05	0.00042	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—MDM2—bone cancer	1.52e-05	0.000407	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—GSTP1—bone cancer	1.52e-05	0.000406	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—BRAF—bone cancer	1.48e-05	0.000395	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling by GPCR—EGFR—bone cancer	1.43e-05	0.000383	CbGpPWpGaD
Tizanidine—ADRA2A—Metabolism—PTGS2—bone cancer	1.43e-05	0.000381	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—JUN—bone cancer	1.42e-05	0.000379	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—MMP9—bone cancer	1.38e-05	0.000369	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—JUN—bone cancer	1.32e-05	0.000354	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—MMP9—bone cancer	1.29e-05	0.000344	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—MDM2—bone cancer	1.24e-05	0.000331	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—EGFR—bone cancer	1.11e-05	0.000298	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—JUN—bone cancer	1.08e-05	0.000287	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—MMP9—bone cancer	1.05e-05	0.00028	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—EGFR—bone cancer	1.04e-05	0.000278	CbGpPWpGaD
Tizanidine—ADRA2B—Signaling Pathways—TP53—bone cancer	9.35e-06	0.00025	CbGpPWpGaD
Tizanidine—ADRA2C—Signaling Pathways—TP53—bone cancer	8.74e-06	0.000234	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—EGFR—bone cancer	8.45e-06	0.000226	CbGpPWpGaD
Tizanidine—CYP1A2—Metabolism—PTGS2—bone cancer	7.87e-06	0.00021	CbGpPWpGaD
Tizanidine—ADRA2A—Signaling Pathways—TP53—bone cancer	7.1e-06	0.00019	CbGpPWpGaD
